BioPharma Credit PLC
26 August 2026
26
August 2026
BIOPHARMA CREDIT PLC
(the "Company")
NOTICE OF HALF YEAR RESULTS
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its Half Year Results for the period ended 30 June 2026 on Thursday 24 September 2026.
A management presentation for sell side analysts will be delivered at 15:00 BST through a webcast facility. To register to attend or request details, RSVP to biopharmacredit@buchanan.uk.com.
Investor Presentation - Investor Meet Company
The Company is also pleased to announce that the investment adviser will also provide a live presentation for investors relating to the Half Year Results via Investor Meet Company on 25 September 2026 at 14:00 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 24 September 2026, 09:00 BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet BioPharma Credit PLC via:
https://www.investormeetcompany.com/biopharma-credit-plc/register-investor
Investors who already follow BioPharma Credit PLC on the Investor Meet Company platform will automatically be invited.
-Ends-
Enquiries:
BioPharma Credit plc
via MUFG Corporate Governance Limited
Company Secretary
+44 (0) 333 300 1932
Burson Buchanan
Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.